代谢功能障碍相关脂肪性肝病促进乙型肝炎表面抗原清除和血清学转换
研究连续纳入4084例未治疗的HBeAg阴性慢性乙型肝炎患者,比较合并与不合并MASLD者的HBsAg清除/血清学转换累积发生率。中位随访5.0年,MASLD与更高的HBsAg清除率(aHR 1.43)和血清学转换率(aHR 1.37)相关,代谢异常个数有叠加效应。
要点
- MASLD与HBsAg清除率升高相关(aHR 1.43,95%CI 1.10-1.85,P=.007)。
- MASLD与HBsAg血清学转换率升高相关(aHR 1.37,95%CI 1.00-1.86,P=.049)。
- 代谢功能异常个数对HBsAg清除有叠加促进作用。
核心结论
- 在未治疗的HBeAg阴性慢性乙型肝炎患者中,合并MASLD与更高的HBsAg清除率和血清学转换率相关;代谢功能异常对CHB的功能性治愈有叠加效应。
研究设计与样本
- 连续纳入2006年至2021年未治疗的HBeAg阴性慢性乙型肝炎患者4084例,按新提出的疾病标准定义MASLD,比较MASLD组与非MASLD组的HBsAg清除/血清学转换累积发生率及相关因素。
主要发现
- 基线时合并MASLD组(n=887)的HBsAg和HBV DNA水平显著低于非MASLD组(n=3197)。
- 中位随访5.0年,MASLD与更高的HBsAg清除可能性相关(aHR 1.43,95%CI 1.10-1.85,P=.007)。
- MASLD组HBsAg血清学转换率高于非MASLD组(aHR 1.37,95%CI 1.00-1.86,P=.049)。
- 敏感性分析中,间歇性MASLD患者的HBsAg清除概率居中。
- 经逆概率治疗加权(IPTW)平衡临床和病毒学特征后,MASLD仍与更高的HBsAg清除率相关(IPTW校正HR 1.41,95%CI 1.09-1.84,P=.010)。
关键数值与推荐
- MASLD定义采用新提出的疾病标准。
- HBsAg清除:MASLD组 vs 非MASLD组,aHR 1.43(95%CI 1.10-1.85,P=.007)。
- HBsAg血清学转换:MASLD组 vs 非MASLD组,aHR 1.37(95%CI 1.00-1.86,P=.049)。
- IPTW校正后HBsAg清除:MASLD组 vs 非MASLD组,HR 1.41(95%CI 1.09-1.84,P=.010)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatitis B surface antigen (HBsAg) seroclearance is the goal of functional cure for hepatitis B virus (HBV) infection. However, the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on this favorable outcome remains unclear. METHODS: Patients with chronic hepatitis B (CHB) were consecutively recruited. MASLD was defined by the newly proposed disease criteria. Cumulative incidences and associated factors of HBsAg seroclearance/seroconversion were compared between the MASLD and non-MASLD groups. RESULTS: From 2006 to 2021, 4084 treatment-naive hepatitis B e antigen (HBeAg)-negative CHB patients were included. At baseline, CHB patients with concurrent MASLD (n = 887) had significantly lower levels of HBsAg and HBV DNA than the non-MASLD group (n = 3197). During a median follow-up of 5.0 years, MASLD was associated with a higher likelihood of HBsAg seroclearance (adjusted hazard ratio [aHR], 1.43; 95% confidence interval [CI], 1.10-1.85; P = .007), and the accumulation of individual metabolic dysfunctions additively facilitated HBsAg seroclearance. In addition, a higher rate of HBsAg seroconversion was observed in patients with MASLD versus those without MASLD (aHR, 1.37; 95% CI, 1.00-1.86; P = .049). In sensitivity analysis, patients with intermittent MASLD had an intermediate probability of HBsAg seroclearance. After balancing clinical and virologic profiles by inverse probability of treatment weighting (IPTW), MASLD was still associated with a higher HBsAg seroclearance rate (IPTW-adjusted HR, 1.41; 95% CI, 1.09-1.84; P = .010). CONCLUSIONS: In untreated HBeAg-negative CHB patients, concurrent MASLD is associated with higher rates of HBsAg seroclearance and seroconversion. Metabolic dysfunctions have additive effects on the functional cure of CHB.
引用
- Huang SC, Su TH, Tseng TC, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion. Clin Gastroenterol Hepatol. 2023. PMID: 37871842. doi:10.1016/j.cgh.2023.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。